Entacapone - Parkinson's disease

You are here : Home > Formulary Search > Entacapone - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NICE

Restrictions / Comments :

Important

Preferred

Preferred COMT inhibitor

Documentation

Guidelines (National)

NICE NG71 Parkinsons-disease-in-adults

PAD Profile

ChemicalSubstance :

Entacapone

Indication :

Parkinson's disease

Group Name :

Keywords :

Parkinsons disease, PD, COMT inhibitors, catechol-o-methyltransferase inhibitors

Brand Names Include :

Comtess

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Entacapone is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Parkinson's disease.

Committee Recommendations (1)

06 Jun 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

COMT inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

Entacapone is the locally agreed 1st-choice COMT inhibitor (BLUE no information sheet)
Opicapone is the locally agreed 2nd-choice COMT inhibitor (BLUE no information sheet)
Tolcapone is the locally agreed 3rd-choice COMT inhiitor (AMBER shared care)

Initiation is to be carried out in in secondary care and prescribed by a specialist for a minimum of 2 months, doses stabilised and response to treatment reviewed prior to any transfer request to primary care.

Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.